Welcome to our dedicated page for Heartbeam news (Ticker: BEAT), a resource for investors and traders seeking the latest updates and insights on Heartbeam stock.
HeartBeam, Inc. (Symbol: BEAT) is a cutting-edge medical technology company that focuses on developing and commercializing high-resolution ambulatory Electrocardiogram (ECG) solutions. These solutions are designed to detect and monitor cardiac diseases outside traditional healthcare settings, providing critical diagnostic capabilities in a more accessible manner.
HeartBeam's flagship product is an innovative, credit card-sized ECG device that is diagnostically equivalent to a cardiologist reading a patient's 12-lead ECG and examining the patient. This compact device integrates seamlessly with a cloud-based diagnostic expert system, offering a comprehensive and user-friendly solution for cardiac monitoring.
Notably, studies designed by Harvard Medical School faculty have demonstrated that HeartBeam's technology performs on par with, or better than, world-class cardiologists in diagnosing heart attacks. The system features personalized diagnostic thresholds and unique ECG markers that help pinpoint the location of a heart attack on a 3D heart model, enhancing the accuracy and depth of diagnostic information provided to healthcare professionals.
One of the key components of HeartBeam's technology is the iCardiologist application, which uses artificial intelligence and machine learning to continually improve its diagnostic accuracy and predictive capabilities. This application aids cardiologists by providing detailed patient analysis, thereby supporting more informed and timely medical decisions.
HeartBeam has developed a proprietary and patented Vector Electrocardiography (VECG) technology platform, which is the cornerstone of its high-resolution ECG solutions. The company has validated this platform and is in the process of seeking U.S. Food and Drug Administration (FDA) clearance for its initial telehealth products.
With its innovative approach and proven technology, HeartBeam is poised to make significant strides in the field of cardiac care, offering practical solutions that can be utilized outside traditional healthcare environments, thereby broadening access to critical diagnostic tools and improving patient outcomes.
Latest News: Source: HeartBeam, Inc.
- ------
- ------
- ------
HeartBeam, Inc. (NASDAQ: BEAT) has entered a professional services agreement with Triple Ring Technologies for the development of a Telehealth 3D vector ECG collection device aimed at remote heart attack monitoring. This partnership will span five phases and is scheduled for FDA 510k submission in Q4 2022. The device is designed for patient use at home, providing crucial ECG data to physicians in real-time. With over 18 million people in the U.S. suffering from coronary artery disease, this innovative solution addresses a significant need in cardiac care.
HeartBeam, Inc. (NASDAQ: BEAT) will conduct a conference call on
HeartBeam, Inc. (NASDAQ: BEAT) has announced a Business Associate Agreement and Clinical Trial Agreement with Phoebe Putney Health System to conduct a pilot study of HeartBeam’s Myocardial Infarction software product. This partnership aims to evaluate the software’s effectiveness in detecting heart attacks in emergency settings. HeartBeam will conduct additional studies and pursue future scientific and commercial collaborations, enhancing its position in the telehealth space for remote heart attack detection.
HeartBeam, Inc. (NASDAQ: BEAT) has announced a partnership with LIVMOR Inc. to develop a HeartBeam branded version of LIVMOR's FDA-cleared Halo+ Remote Patient Monitoring (RPM) platform. This collaboration aims to enhance heart attack detection by customizing the platform for HeartBeam's products. CEO Branislav Vajdic emphasized that using LIVMOR's established platform will expedite the FDA submission of their heart attack detection software, aimed at Emergency Department settings, later this year. This partnership aims to improve the accuracy of myocardial infarction detection.
HeartBeam, Inc. (NASDAQ: BEAT) has established a Scientific Advisory Board (SAB) to enhance its medical studies and product development. The board will be chaired by C. Michael Gibson, an esteemed cardiologist known for his work in cardiovascular research. Dr. Gibson's extensive experience includes leading over 120 clinical trials and contributing to major cardiac drug approvals. This strategic move aims to bolster HeartBeam's proprietary ECG telemedicine technology, focusing on accurate heart attack diagnosis in ambulatory settings.
HeartBeam, Inc. (NASDAQ: BEAT), a digital healthcare company, announced its participation in the H.C. Wainwright BIOCONNECT Conference from January 10-13, 2022. Key executives, including CEO Branislav Vajdic, will conduct video meetings during the event. The conference aims to showcase HeartBeam's innovative ECG telemedicine technology, designed to diagnose cardiovascular diseases effectively outside traditional medical settings. This breakthrough technology targets a significant market need, particularly in diagnosing heart attacks in high-risk patients.
HeartBeam, Inc. (NASDAQ: BEAT) has appointed Alan Baumel as the new Chief Operating Officer, a role focused on product development and regulatory affairs for their innovative ECG telemedicine technology. With over 35 years in the medical device sector, Baumel is expected to enhance HeartBeam's commercialization strategy and accelerate FDA product development. His experience includes leadership roles at Bardy Diagnostics and contributions to improving medical device quality and safety. HeartBeam aims to address significant needs in heart attack detection outside medical institutions.
HeartBeam, Inc. (NASDAQ: BEAT) has successfully closed a $16.5 million IPO, selling 2,750,000 units at $6.00 each. The IPO generated net proceeds of $14.9 million, boosting the company’s cash balance to approximately $15.7 million. HeartBeam aims to advance its FDA-ready telemedicine solutions for cardiovascular assessment, with significant milestones set for 2022 and 2023. Q3 2021 financial results show an increased net loss of $1.2 million, up from $335,000 in Q3 2020, while R&D expenses rose to $105,000 from $57,000 year-over-year.
HeartBeam, Inc. (NASDAQ: BEAT) has successfully closed its initial public offering of 2,750,000 units at $6.00 each, generating net proceeds of
HeartBeam, Inc. (NASDAQ: BEAT) has priced its initial public offering of 2,750,000 units at $6.00 per unit, consisting of one share of common stock and one warrant. The offering is expected to generate
FAQ
What is the current stock price of Heartbeam (BEAT)?
What is the market cap of Heartbeam (BEAT)?
What does HeartBeam, Inc. do?
What is unique about HeartBeam's technology?
How does HeartBeam's iCardiologist application work?
What is VECG technology?
Has HeartBeam's technology been validated?
Is HeartBeam seeking FDA clearance?
What are the benefits of HeartBeam's ECG solutions?
Can HeartBeam's technology locate a heart attack?
How is HeartBeam improving cardiac care?
Where can I find the latest news on HeartBeam, Inc.?
